Replies to post #107731 on Biotech Values

[DewDiligence]

MNTA/NVS/TEVA/MYL—In general, what is the good, bad and ugly regarding the Courts combining the Mylan and Sandoz lawsuits?

It’s a minor negative for MNTA insofar as it delays the start of the Copaxone trial by a few months. In other respects, the decision is essentially neutral for MNTA.

Note that SNY’s Lovenox suits against Teva and Amphastar started out as separate cases and were consolidated by the District Court. This is a common practice in Hatch-Waxman patent cases.